KR102372288B1 - 단백질 키나아제 억제제로서의 아미노티아졸 화합물 - Google Patents

단백질 키나아제 억제제로서의 아미노티아졸 화합물 Download PDF

Info

Publication number
KR102372288B1
KR102372288B1 KR1020197038421A KR20197038421A KR102372288B1 KR 102372288 B1 KR102372288 B1 KR 102372288B1 KR 1020197038421 A KR1020197038421 A KR 1020197038421A KR 20197038421 A KR20197038421 A KR 20197038421A KR 102372288 B1 KR102372288 B1 KR 102372288B1
Authority
KR
South Korea
Prior art keywords
cancer
compound
alkyl
atom bonded
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197038421A
Other languages
English (en)
Korean (ko)
Other versions
KR20200014350A (ko
Inventor
추안 시
위어-토른 지앙
후이-젠 차이
Original Assignee
내셔날 헬스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내셔날 헬스 리서치 인스티튜트 filed Critical 내셔날 헬스 리서치 인스티튜트
Publication of KR20200014350A publication Critical patent/KR20200014350A/ko
Application granted granted Critical
Publication of KR102372288B1 publication Critical patent/KR102372288B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197038421A 2017-06-13 2018-06-13 단백질 키나아제 억제제로서의 아미노티아졸 화합물 Active KR102372288B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518855P 2017-06-13 2017-06-13
US62/518,855 2017-06-13
PCT/US2018/037221 WO2018231910A1 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20200014350A KR20200014350A (ko) 2020-02-10
KR102372288B1 true KR102372288B1 (ko) 2022-03-08

Family

ID=64562741

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038421A Active KR102372288B1 (ko) 2017-06-13 2018-06-13 단백질 키나아제 억제제로서의 아미노티아졸 화합물

Country Status (13)

Country Link
US (1) US10300061B2 (cg-RX-API-DMAC7.html)
EP (1) EP3638237B1 (cg-RX-API-DMAC7.html)
JP (1) JP6979595B2 (cg-RX-API-DMAC7.html)
KR (1) KR102372288B1 (cg-RX-API-DMAC7.html)
CN (1) CN110831596B (cg-RX-API-DMAC7.html)
AU (1) AU2018284249B2 (cg-RX-API-DMAC7.html)
CA (1) CA3064081C (cg-RX-API-DMAC7.html)
ES (1) ES2949616T3 (cg-RX-API-DMAC7.html)
MX (1) MX393992B (cg-RX-API-DMAC7.html)
MY (1) MY201291A (cg-RX-API-DMAC7.html)
TW (1) TWI667236B (cg-RX-API-DMAC7.html)
WO (1) WO2018231910A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202000107B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
KR20220103744A (ko) * 2019-11-14 2022-07-22 에이2에이 파마수티칼스, 잉크. 항암제로서 tacc3을 표적으로 하는 이속사졸 유도체
JP7691991B2 (ja) * 2020-03-06 2025-06-12 ナショナル・ヘルス・リサーチ・インスティテューツ ピリミジン化合物及びその薬学的使用
US11299489B1 (en) 2020-11-19 2022-04-12 National Health Research Institutes Thiazole compounds as protein kinase inhibitors
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
CA3246244A1 (en) 2022-03-24 2023-09-28 A2A Pharmaceuticals, Inc. CANCER COMPOSITIONS AND TREATMENT METHODS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106437A2 (en) 2005-04-04 2006-10-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
WO2007141571A2 (en) 2006-06-05 2007-12-13 Merck Sharp & Dohme Limited Aminothiazole derivatives as inhibitors of mark
WO2013014170A1 (en) 2011-07-27 2013-01-31 Ab Science Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558609A4 (en) 2002-10-30 2008-05-28 Merck & Co Inc KINASE INHIBITORS
JP2008543754A (ja) * 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
WO2008033746A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106437A2 (en) 2005-04-04 2006-10-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
WO2007141571A2 (en) 2006-06-05 2007-12-13 Merck Sharp & Dohme Limited Aminothiazole derivatives as inhibitors of mark
WO2013014170A1 (en) 2011-07-27 2013-01-31 Ab Science Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Drug Metabolism and Disposition, 2008, 제36권, 제7호, 페이지 1357-1364

Also Published As

Publication number Publication date
RU2019137573A3 (cg-RX-API-DMAC7.html) 2021-07-23
EP3638237B1 (en) 2023-04-19
EP3638237A4 (en) 2021-01-13
BR112019026577A8 (pt) 2023-04-11
US10300061B2 (en) 2019-05-28
CA3064081A1 (en) 2018-12-20
MY201291A (en) 2024-02-15
TWI667236B (zh) 2019-08-01
ES2949616T3 (es) 2023-10-02
JP2020523348A (ja) 2020-08-06
AU2018284249B2 (en) 2021-06-24
MX2019014845A (es) 2020-08-06
CA3064081C (en) 2023-03-21
KR20200014350A (ko) 2020-02-10
WO2018231910A1 (en) 2018-12-20
MX393992B (es) 2025-03-24
CN110831596A (zh) 2020-02-21
EP3638237A1 (en) 2020-04-22
ZA202000107B (en) 2020-12-23
US20180353509A1 (en) 2018-12-13
NZ759327A (en) 2021-08-27
RU2019137573A (ru) 2021-05-24
AU2018284249A1 (en) 2019-12-12
TW201906836A (zh) 2019-02-16
CN110831596B (zh) 2025-01-24
BR112019026577A2 (pt) 2020-06-23
JP6979595B2 (ja) 2021-12-15

Similar Documents

Publication Publication Date Title
CN110772638B (zh) Alk抑制剂与egfr抑制剂在制备治疗癌症的药物中的用途
CN109369671B (zh) 作为Raf激酶和/或Raf激酶二聚体抑制剂的稠合三环脲类化合物
US10300061B2 (en) Aminothiazole compounds as protein kinase inhibitors
EP2498607B1 (en) Kinase inhibitors
BR112012010085B1 (pt) composto, quantidade terapeuticamente eficaz de um composto, formulação farmacêutica
EP3952865A1 (en) Heterocyclic compounds as kinase inhibitors for therapeutic uses
EP3411035A1 (en) Aminothiazole compounds and use thereof
AU2015290007B2 (en) Fused quinoline compunds as pi3k, mTor inhibitors
KR20210066839A (ko) Fgfr4 저해제 및 그것의 용도
KR102325899B1 (ko) 퀴나졸린 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
MX2014009524A (es) Derivados de triazolopiridina como un inhibidor de quinasa tirosina.
CN115707704B (zh) 氘代稠合三环类化合物及其组合物和用途
RU2772645C2 (ru) Аминотиазольные соединения в качестве ингибиторов протеинкиназ
TWI750905B (zh) 噻唑化合物作為蛋白質激酶抑制劑
US11299489B1 (en) Thiazole compounds as protein kinase inhibitors
HK40017909A (en) Aminothiazole compounds as protein kinase inhibitors
NZ759327B2 (en) Aminothiazole compounds as protein kinase inhibitors
HK40017909B (en) Aminothiazole compounds as protein kinase inhibitors
US20180244695A1 (en) Quinoline derivative, and pharmaceutical composition, preparation method and use thereof
BR112019026577B1 (pt) Compostos aminotiazol, composição farmacêutica e uso como inibidores de proteína quinase e no tratamento de câncer
KR20250041906A (ko) Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물
KR20260062876A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
HK40021582A (en) Use of alk inhibitor and egfr inhibitor in preparation of a medicine for treating cancer
HK40021582B (en) Use of alk inhibitor and egfr inhibitor in preparation of a medicine for treating cancer
HK1263053A1 (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210527

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20210527

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211008

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20220207

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220218

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220303

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220304

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250305

Start annual number: 4

End annual number: 4